Stock ACIU AC IMMUNE SA
Add to a list
To use this feature you must be a member
Log inSign up

Company AC Immune SA

Equities

ACIU

CH0329023102

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.35 USD +2.62% Intraday chart for AC Immune SA -0.42% -53.00%
Mar. 15 AC Immune Files $350 Million Mixed Shelf MT
Mar. 14 AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Number of employees: 147

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapeutic and Diagnostic Products
100.0 %
4 100.0 % 16 100.0 % +299.75%

Sales per region

USD in Million2022Weight2023Weight Delta
Switzerland
100.0 %
4 100.0 % 16 100.0 % +299.75%

Managers

Managers TitleAgeSince
Andrea Pfeifer FOU
 Founder 66 03-02-12
Christopher Roberts DFI
 Director of Finance/CFO 35 18-12-31
Nuno Mendonça CTO
 Chief Tech/Sci/R&D Officer 42 23-09-30
Oliver Sol CTO
 Chief Tech/Sci/R&D Officer 58 15-12-31
Madiha Derouazi CTO
 Chief Tech/Sci/R&D Officer 51 Dec. 31
Piergiorgio Donati CTO
 Chief Tech/Sci/R&D Officer 54 18-05-31
Jean-Fabien Monin ADM
 Chief Administrative Officer 54 09-02-28
Gary Waanders IRC
 Investor Relations Contact 60 -
Howard Donovan HRO
 Human Resources Officer 49 22-04-17
Julian Snow PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Douglas Williams CHM
 Chairman 66 17-12-31
Carl June BRD
 Director/Board Member 70 20-11-19
Werner Lanthaler BRD
 Director/Board Member 56 18-07-05
Andrea Pfeifer FOU
 Founder 66 03-02-12
Monika Bütler BRD
 Director/Board Member 63 21-10-28
Roy Ervin Twyman BRD
 Director/Board Member 68 18-12-31
Monica Shaw BRD
 Director/Board Member 46 21-10-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 104,441,787 57,662,113 ( 55.21 %) 5,243,958 ( 5.021 %) 55.21 %

Shareholders

NameEquities%Valuation
dievini Hopp BioTech holding GmbH & Co. KG
16.45 %
16,316,742 16.45 % 48 M $
BVF, Inc.
14.69 %
14,571,236 14.69 % 43 M $
Rudolf Maag
12.10 %
11,999,999 12.10 % 36 M $
MIG Verwaltungs AG
6.631 %
6,578,100 6.631 % 19 M $
Avidity Partners Management LP
4.505 %
4,469,080 4.505 % 13 M $
ELI LILLY AND COMPANY
3.645 %
3,615,328 3.645 % 11 M $
Andrea Pfeifer
2.441 %
2,421,226 2.441 % 7 M $
BlackRock Advisors LLC
2.334 %
2,314,910 2.334 % 7 M $
Redmile Group LLC
2.016 %
2,000,000 2.016 % 6 M $
Morgan Stanley Capital Services LLC
1.771 %
1,757,240 1.771 % 5 M $

Company contact information

AC Immune SA

EPFL Innovation Park Building B

1015, Lausanne

+41 21 345 91 21

http://www.acimmune.com
address AC Immune SA(ACIU)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for AC Immune SA

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.15 CHF
Average target price
9.424 CHF
Spread / Average Target
+338.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AC IMMUNE SA Stock AC Immune SA
-53.00% 221M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACIU Stock
  4. Company AC Immune SA